Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.
An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.
People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.